Dr. Reddy's, Rheoscience PPAR deal

RDY and Rheoscience (Roedovre, Denmark) partnered to co-develop and commercialize balaglitazone ( DRF 2593), a partial PPAR gamma agonist that has completed Phase II testing to treat Type II diabetes. RDY will pay a share of the development costs. Rheoscience will be responsible for regulatory submissions in the U.S. and will have marketing rights in the EU and China. RDY will have rights elsewhere. Rheoscience is eligible for a milestone upon U.S. approval. Both companies are eligible for royalties. ...